Abstract
Malignant gliomas are the most frequent malignant brain tumours and the median overall survival is still only 15 months despite combination of radio and chemotherapy and introduction of novel molecular-based therapies. We report on our experience with the antiangiogenic therapy with Bevacizumab (Avastin®) 10 mg/kg in combination with Irinotecan 125 mg/m2 as second-line chemotherapy in 32 patients with recurring high-grade gliomas. The results in 32 patients demonstrated radiological response in 68%, 19 completely evaluable patients (11/19 had more than one relapse) had a median TTP of 26 weeks, a 6-month PFS of 58%, a median OS of 11 months and a 9-month OS of 68%. Toxicity of this treatment was mild; no wound healing disorder or tumour bleeding appeared. Steroid dose could be significantly reduced. This concept of combination of anti-angiogenic and cytostatic agents is currently the most promising second-line therapy. Finally, an outlook to future strategies is given.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
